Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accounts Payables (2021 - 2025)

InMed Pharmaceuticals' Accounts Payables history spans 5 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 86.55% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 86.55%, while the annual FY2025 figure was $1.4 million, 124.26% up from the prior year.
  • Accounts Payables reached $1.1 million in Q4 2025 per INM's latest filing, up from $369088.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $2.1 million in Q4 2021 to a low of $369088.0 in Q3 2025.
  • Average Accounts Payables over 5 years is $1.1 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: tumbled 69.59% in 2023, then surged 166.31% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $2.1 million in 2021, then crashed by 44.96% to $1.1 million in 2022, then increased by 12.41% to $1.3 million in 2023, then tumbled by 55.38% to $574563.0 in 2024, then soared by 86.55% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Accounts Payables are $1.1 million (Q4 2025), $369088.0 (Q3 2025), and $1.4 million (Q2 2025).